drugset / Trial / NCT00042068

A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid Arthritis

NCT00042068

Phase 3 Completed 1000 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blind

Summary

A 12-week trial consisting of 5 visits (6 if follow up is needed) to find out how effective and safe three different doses of meloxicam are compared with placebo in Rheumatoid Arthritis. Patient will take one dose of study medication daily.

Timeline

Start
2002-06
Primary completion
Completion
2003-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Meloxicam Small molecule 7.5 mg
Subject Meloxicam Small molecule 15 mg
Subject Meloxicam Small molecule 22.5 mg

Indications